NT5E and neoplasm: As CD73 expression is associated with cancer progression, poor clinical outcomes, and resistance to chemotherapy [14,15,16], targeting the CD73–adenosine axis in the tumor microenvironment has been actively studied as an attractive therapeutic strategy to inhibit tumor progression and improve cancer immunotherapy [29].